Institutional members access full text with Ovid®

Share this article on:

UPDATE ON THE MEDICAL MANAGEMENT OF PARKINSON DISEASE

Fang, John Y.

doi: 10.1212/01.CON.0000348902.87091.ad
Article

Dopaminergic agents remain the principal treatments for patients with Parkinson disease (PD). In many patients, however, a combination of relatively resistant motor symptoms, motor complications such as dyskinesias, or nonmotor symptoms such as dysautonomia may lead to substantial disability in spite of dopaminergic therapy. This chapter will review both dopaminergic and nondopaminergic therapies for motor and nonmotor symptoms in PD.

Although the basic principles of pharmacotherapy for the motor symptoms of PD have largely remained unchanged over the past decade, several new therapies have become available to refine treatment. In addition, there has been an increasing interest in agents targeting nonmotor symptoms, such as dementia and sleepiness. As patients with PD live longer and acquire additional comorbidities, addressing these nonmotor symptoms has become increasingly important. In this chapter, the major antiparkinsonian dopaminergic compounds will be reviewed, followed by a patient-focused guide to implementation of these treatments as part of an overall management plan.

Relationship Disclosure: Dr Fang has received research support from the University of South Florida for a Lyrica in essential tremor project.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Fang discusses the unlabeled use of medication for the management of Parkinson disease. All unlabeled uses are disclosed in the chapter, where applicable.

© 2010 American Academy of Neurology
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website